You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.
Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announced the last patient was enrolled in the Phase IIb study for its first-in-class compound Sepranolone for premenstrual dysphoric disorder (PMDD). Top-line results are on track for late March 2020.
Full PDFAsarina Pharma AB (publ) (ASAP: FN Stockholm) today announces the FDA has approved the IND for its lead compound Sepranolone in menstrual migraine. It is an important confirmation of Sepranolone’s strong safety profile.
Full PDF(Stockholm, June 4, 2019) Asarina Pharma AB (publ) today announces that it will, pursuant to the authorisation granted by the Annual General Meeting on 8 May 2019, issue 246,434 new shares to Ergomed plc (“Ergomed”), the CRO carrying out its Phase IIb PMDD study.
Full PDF(Stockholm May 20, 2019) Asarina Pharma CEO Peter Nordkild: “We have made a strong start to 2019. This Quarter we have strengthened our team and capabilities, yet still maintained strict financial management – leading to a solid cash position at the end of the First Quarter.”
Full PDF(Stockholm May 8, 2019) On 8 May 2019, the Annual General Meeting (”AGM”) of Asarina Pharma AB (publ) was held in Stockholm. Read below for a summary of the decisions made.
Full PDF